Generics In September 2018, the US Food and Drug Administration issued 54 product-specific guidance documents containing methodologies and evidence to support the development of generic drugs.1 Each document provides the latest in a series of steps undertaken by the FDA and the US Congress to combat high drug prices by encouraging the production of quality generic drugs, writes Dr Nicola Davies in her monthly FDA blog for The Pharma Letter. 10 November 2018